University of Pennsylvania School of Engineering and Applied Science Dec 18 2024 Penn Engineers have modified lipid nanoparticles (LNPs) -; the revolutionary technology behind the COVID-19 mRNA vaccines -; to not only cross the blood-brain barrier (BBB) but also to target specific types of cells, including neurons. This breakthrough marks a significant step toward potential next-generation treatments for neurological diseases like Alzheimer's and Parkinson's. In a new paper in Nano Letters ,

Tag-uri: Coronavirus